LYS.PA - Lysogene S.A.

Paris - Paris Delayed Price. Currency in EUR
1.6900
+0.0700 (+4.32%)
As of 10:52AM CEST. Market open.
Stock chart is not supported by your current browser
Previous Close1.6200
Open1.6200
BidN/A x N/A
AskN/A x N/A
Day's Range1.6200 - 1.6900
52 Week Range1.3950 - 2.5300
Volume1,501
Avg. Volume5,115
Market Cap21.773M
Beta (3Y Monthly)0.05
PE Ratio (TTM)N/A
EPS (TTM)-0.8690
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.30
  • Business Wire

    Lysogene Appoints Mr. Stéphane Durant des Aulnois as Chief Financial Officer

    Lysogene (LYS.PA) (FR0013233475 – LYS), a pioneering Phase 3 biopharmaceutical company specializing in gene therapy targeting central nervous system (CNS) diseases, today announced the appointment of Stéphane Durant des Aulnois as Chief Financial Officer. In this position, Stéphane will supervise all financial activities, as well as Alliance Management and Business Development initiatives. Stéphane will be a member of the Executive Committee.

  • Business Wire

    Lysogene Reports First Half 2019 Financial Results and Provides Operational Update

    Lysogene (LYS.PA) (FR0013233475 – LYS), a pioneering, Phase 3, biopharmaceutical company specializing in gene therapy targeting central nervous system (CNS) diseases, today announced financial results and major advancements for 2019. “The first half of 2019 was highlighted by progress made in both of our MPS IIIA and GM1 programs,” said Karen Aiach, Founder, Chairman and Chief Executive Officer. “We have already treated nine children in our international MPS IIIA Phase 2-3 trial, our partnership with Sarepta therapeutics considerably reinforces our presence and we have progressed our GM1 gangliosidosis pre-IND discussions with regulatory authorities.

  • Business Wire

    Lysogene Announces the Appointment of Carole Deffez as New Independent Board Director

    Lysogene (FR0013233475 – LYS) (LYS.PA), a pioneering Phase 3 biopharmaceutical company specializing in gene therapy targeting central nervous system (CNS) diseases, today announced that it is expanding its Board of Directors through the appointment of Carole Deffez as independent Director. All Directors, with the exception of Karen Aiach, are independent directors. “We are honored to welcome Carole on our Board of Directors.

  • Business Wire

    Lysogene: A Pivotal Year 2019 for Lysogene’s MPS IIIA Phase 2-3 Clinical Trial

    Lysogene (FR0013233475 – LYS) (LYS.PA), a pioneering biopharmaceutical company specializing in gene therapy targeting central nervous system (CNS) diseases, today announced major advancements, for their Sanfilippo syndrome type A (MPS IIIA) clinical program. “Having launched our Phase 2-3 clinical trial in MPS IIIA, enrolled half of the intended study population and completed our two-year natural history study to be used as the control group, so far 2019 has been a year of significant progress.

  • What Kind Of Shareholders Own Lysogene S.A. (EPA:LYS)?
    Simply Wall St.

    What Kind Of Shareholders Own Lysogene S.A. (EPA:LYS)?

    The big shareholder groups in Lysogene S.A. (EPA:LYS) have power over the company. Generally speaking, as a company...

  • Business Wire

    Lysogene Announces Presentations at Upcoming Scientific and Family Conferences

    Presentations to Highlight Results from Natural History and Treatment Studies for MPS IIIA and IND-enabling studies in GM1 gangliosidosis

  • GlobeNewswire

    Lysogene and Sarepta Therapeutics Announce Dosing of the First Patient in AAVance, a Phase 2/3 Clinical Trial Investigating LYS-SAF302, a Gene Therapy for the Treatment of MPS IIIA (Sanfilippo Syndrome Type A)

    Lysogene (FR0013233475 – LYS), a pioneering biopharmaceutical company specializing in gene therapy targeting central nervous system (CNS) diseases, and Sarepta Therapeutics, Inc. (SRPT), the leader in precision genetic medicine for rare diseases, announced today that the first patient has been dosed in AAVance, a global Phase 2-3 clinical trial of LYS-SAF302, a gene therapy for the treatment of Mucopolysaccharidosis Type IIIA (MPS IIIA). AAVance is a single-arm trial aimed at evaluating the effectiveness of a one-time delivery of a recombinant adeno-associated virus vector rh.10 carrying the N-sulfoglucosamine sulfohydrolase (SGSH) gene.

  • Can We See Significant Insider Ownership On The Lysogene S.A. (EPA:LYS) Share Register?
    Simply Wall St.

    Can We See Significant Insider Ownership On The Lysogene S.A. (EPA:LYS) Share Register?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! A look at the shareholders of LysogeneRead More...